Compare SAH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | AUPH |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 1997 | 2014 |
| Metric | SAH | AUPH |
|---|---|---|
| Price | $78.64 | $15.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $78.25 | $17.25 |
| AVG Volume (30 Days) | 192.7K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | ★ 1.79 | 0.25 |
| Revenue | ★ $9,951,630,000.00 | $283,055,000.00 |
| Revenue This Year | $4.61 | $17.54 |
| Revenue Next Year | $4.16 | $15.74 |
| P/E Ratio | ★ $45.27 | $62.74 |
| Revenue Growth | 0.86 | ★ 20.38 |
| 52 Week Low | $54.11 | $7.29 |
| 52 Week High | $89.38 | $16.88 |
| Indicator | SAH | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 54.09 |
| Support Level | $77.10 | $14.26 |
| Resistance Level | $81.51 | $16.39 |
| Average True Range (ATR) | 3.27 | 0.72 |
| MACD | 0.35 | -0.06 |
| Stochastic Oscillator | 64.62 | 63.27 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 111 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025's revenue was $15.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.